| Literature DB >> 33223840 |
Qiqi An1, Wanmei Song1, Jinyue Liu2, Ningning Tao3, Yao Liu4, Qianyun Zhang1, Tingting Xu4, Shijin Li1, Siqi Liu1, Yifan Li4, Chunbao Yu5, Huaichen Li1,4,6.
Abstract
BACKGROUND: With an aging population, China is facing a huge burden of elderly patients with drug resistant tuberculosis (DR-TB), which has become a significant obstacle for the global TB control. There is still little study on DR-TB in the elderly in China so far. Thus, more research on the epidemiological characteristics and trend of primary DR-TB among the elderly will be necessary.Entities:
Keywords: chi-square regression; epidemiology; linear regression; primary DR-TB; the elderly
Year: 2020 PMID: 33223840 PMCID: PMC7671465 DOI: 10.2147/IDR.S277203
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Sociodemographic and Clinical Characteristics of Elderly and Non-Elderly Primary TB Patients, Shandong Province, China, 2004–2019
| Characteristic | Age<60 Years, No.(%)n=8183 | Characteristic | Age≥60 Years, No. (%)n=4368 | Age≥60 vs Age<60 (total) | Age≥60 vs Age<60 (DR-TB) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total n=8183 | DR-TB n=1600 | Susceptible TB n=6583 | OR(95% CI) | P value | Total n=4368 | DR-TB n=751 | Susceptible TB n=3617 | OR(95% CI) | P value | OR(95% CI) | P value | OR(95% CI) | P value | ||||
| Sex (n=8181/n=1600/n=6581) | Female | 1823 (22.28) | 314(19.63) | 1509(22.93) | No reference | No reference | Sex(n=4367/n=751/n=3616) | Female | 535 (12.25) | 80 (10.65) | 455 (12.58) | No reference | No reference | No reference | No reference | No reference | No reference |
| Male | 6358 (77.72) | 1286(80.38) | 5072(77.07) | 1.218(1.063–1.396) | 0.004 | Male | 3832 (87.75) | 671 (89.35) | 3161 (87.42) | 1.207(0.939–1.553) | 0.143 | 2.054(1.850–2.280) | <0.000 | 2.048(1.575–2.663) | <0.000 | ||
| Cavity (n=7126/n=1397/n=5729) | No | 4224 (59.28) | 792(56.69) | 3432(59.91) | No reference | No reference | Cavity(n=3778/n=657/n=3121) | No | 2422 (64.11) | 413 (62.86) | 2009 (64.37) | No reference | No reference | No reference | No referance | No reference | No reference |
| Yes | 2902 (40.72) | 605(43.31) | 2297(40.09) | 1.141(1.014–1.285) | 0.028 | Yes | 1356 (35.89) | 244(37.14) | 1112 (35.63) | 1.067(0.897–1.271) | 0.464 | 0.815(0.751–0.884) | <0.000 | 0.773(0.639–0.936) | 0.008 | ||
| Smoking (n=4801/n=922/n=3879) | No | 3722 (77.53) | 719(77.98) | 3003(77.42) | No reference | No reference | Smoking(n=2680/n=438/n=2242) | No | 1888 (70.45) | 307(70.09) | 1581 (70.52) | No reference | No reference | No reference | No reference | No reference | No reference |
| Yes | 1079 (22.47) | 203(22.02) | 876 (22.58) | 0.968(0.814–1.151) | 0.711 | Yes | 792 (29.55) | 131(29.91) | 661 (29.48) | 1.021(0.816–1.277) | 0.858 | 1.447(1.300–1.611) | <0.000 | 1.511(1.169–1.954) | 0.002 | ||
| Drinking (n=4761/n=917/n=3844) | No | 3809 (80.00) | 752(82.01) | 3057 (79.53) | No reference | No reference | Drinking(n=2667/n=438/n=1886) | No | 2074 (77.77) | 342(78.08) | 1732 (91.83) | No reference | No reference | No reference | No reference | No reference | No reference |
| Yes | 952 (20.00) | 165(17.99) | 787 (20.47) | 0.852(0.708–1.026) | 0.092 | Yes | 593 (22.23) | 96(21.92) | 497 (26.35) | 0.978(0.764–1.253) | 0.861 | 1.144(1.019–1.284) | 1.279(0.965–1.696) | 0.087 | |||
| Type (n=8183/n=1600/n=6583) | Extrapulmonary TB | 23 (0.28) | 4(0.25) | 19 (0.29) | No reference | No reference | Type(n=4368/n=750/n=3618) | Extrapulmonary TB | 16 (0.37) | 2(0.27) | 14 (0.39) | No reference | No reference | No reference | No reference | No reference | No reference |
| Pulmonary TB | 8160 (99.72) | 1596(99.65) | 6564 (99.71) | 1.115(0.392–3.400) | 0.794 | Pulmonary TB | 4352 (99.63) | 748(99.73) | 3604 (99.61) | 1.453(0.330–6.406) | 0.622 | 0.767(0.405–1.453) | 0.415 | 0.937(0.171–5.129) | 0.941 | ||
| COPD (n=6033/n=1199/n=4834) | No | 6007 (99.57) | 1196(99.75) | 4811(99.52) | No reference | No reference | COPD(n=3340/n=460/n=2880) | No | 3184(95.33) | 434(94.35) | 2750(95.49) | No reference | No reference | No reference | No reference | No reference | No reference |
| Yes | 26 (0.43) | 3(0.25) | 23(0.48) | 0.350(0.082–1.486) | 0.155 | Yes | 156(4.67) | 26(5.65) | 130(4.51) | 1.267(0.822–1.954) | 0.284 | 11.320(7.457–17.183) | <0.000 | 23.883(7.193–79.305) | <0.000 | ||
| Diabetes (n=6033/n=1199/n=4834) | No | 5683 (94.20) | 1128(94.08) | 4555(94.23) | No reference | No reference | Diabetes(n=3340/n=563/n=2779) | No | 3075(92.07) | 508(90.23) | 2567(53.10) | No reference | No reference | No reference | No reference | No reference | No reference |
| Yes | 350 (5.80) | 71(5.92) | 279(5.77) | 1.028(0.786–1.344) | 0.842 | Yes | 265 (7.93) | 53 (9.41) | 212 (4.39) | 1.263(0.921–1.732) | 0.147 | 1.399(1.186–1.651) | <0.000 | 1.658(1.144–2.402) | 0.008 | ||
Abbreviations: OR, odds ratio; TB, tuberculosis; DR-TB, drug-resistant tuberculosis.
Primary Drug Resistance Profiles of Mycobacterium Tuberculosis Between Elderly People and Non-Elderly People, Shandong, China, 2004–2019
| Drug Resistance | Age<60 Years, No.(%) n=8183 | Age≥60 Years, No.(%) n=4368 | P value |
|---|---|---|---|
| DR-TB (Total) | 1600 (19.55) | 751 (17.19) | 0.001 |
| Any resistance to first-line drugs | No reference | No reference | No reference |
| INH | 873 (10.67) | 446 (10.21) | 0.426 |
| RFP | 415 (5.07) | 136 (3.11) | <0.000 |
| EMB | 131 (1.60) | 56 (1.28) | 0.16 |
| SM | 1143 (13.97) | 469 (10.74) | <0.000 |
| MR-TB (Total) | 962 (11.76) | 488(11.17) | 0.330 |
| INH | 286 (3.50) | 197(4.51) | 0.005 |
| RFP | 72 (0.88) | 23(0.53) | 0.031 |
| EMB | 9 (0.11) | 13 (0.30) | 0.022 |
| SM | 588 (7.19) | 250 (5.72) | 0.002 |
| Others | 7 (0.09) | 5 (0.11) | 0.619 |
| MDR-TB (Total) | 304 (3.72) | 100 (2.29) | <0.000 |
| MDR1:INH+RFP | 55 (0.67) | 35 (0.80) | 0.415 |
| MDR2:INH+RFP+EMB | 11 (0.13) | 2 (0.05) | 0.161 |
| MDR3:INH+RFP+EMB+SM | 69 (0.84) | 26 (0.60) | 0.127 |
| MDR4:INH+RFP+SM | 153 (1.87) | 33 (0.76) | <0.000 |
| Others | 16 (0.20) | 4 (0.09) | 0.174 |
| PDR-TB(Total) | 343(4.19) | 163 (3.73) | 0.212 |
| PDR1:INH+EMB | 9(0.11) | 5 (0.11) | 0.943 |
| PDR2:INH+SM | 272(3.32) | 138 (3.16) | 0.621 |
| PDR3:INH+EMB+SM | 11(0.13) | 6 (0.14) | 0.966 |
| PDR4:RFP+EMB | 5 (0.06) | 2 (0.05) | 0.729 |
| PDR5:RFP+SM | 36 (0.44) | 10 (0.23) | 0.067 |
| PDR6:RFP+EMB+SM | 4 (0.05) | 1 (0.02) | 0.497 |
| Others | 6 (0.07) | 1(0.02) | 0.254 |
Abbreviations: EMB, ethambutol; INH, isoniazid; NA, not applicable; RFP, rifampin; SM, streptomycin; TB, tuberculosis; DR-TB, drug-resistant tuberculosis; MR-TB, mono-resistant tuberculosis; MDR-TB, multi-resistant tuberculosis; PDR-TB, polydrug resistant tuberculosis.
Figure 1Trends for the quantity and proportions of different subgroups among the total elderly primary DR-TB cases, Shandong, China, 2004–2019*. (A) Trends for MR-TB, MDR-TB, PDR-TB among the elderly with primary TB; (B) Trends for the elderly primary DR-TB cases of different sex (male or female); (C) Trends for primary DR-TB cases with or without cavity; (D) Trends for primary DR-TB cases with or without smoking history; (E) Trends for primary DR-TB cases with or without drinking history; The proportions of each subgroups were calculated as follows: (the quantity of each subgroups/the quantity of the total elderly primary DR-TB subgroups in the same year) × 100%; The χ2 and linear regression results are shown in Table 4.
Figure 2Overall first-line drug resistance for INH, RIF, EMB, and SM among the elderly cases of primary drug-resistant tuberculosis in Shandong, China, 2004–2019. The proportions of INH-, RIF-, EMB-, and SM-resistance were calculated as follows: (the quantity of each subgroups/the quantity of total the elderly primary DR-TB subgroups in the same year) × 100%; The χ2 and linear regression results are shown in Table 4.
Changes in Proportions of Different Primary Drug-Resistant Mycobacterium Tuberculosis Subgroups Among the Elderly, Shandong Province, China, 2004–2019
| Subgroups | P value | R2 | X-Coefficient | SE | |
|---|---|---|---|---|---|
| MR-TB (%) | 1.793 | 0.181 | 0.0241 | −0.003437 | 0.67614 |
| MDR-TB (%) | 1.179 | 0.278 | 0.0098 | 0.002233 | 0.1324 |
| PDR-TB (%) | 0.486 | 0.486 | 0.0057 | 0.001366 | 0.18946 |
| Male (%) | 3.941 | 0.047 | 0.0901 | −0.00307 | 0.9315 |
| Female (%) | 3.941 | 0.047 | 0.0901 | 0.00307 | 0.0685 |
| Cavity (%) | 97.545 | <0.000 | 0.6069 | 0.024115 | 0.076289 |
| Non-cavity (%) | 208.201 | <0.000 | 0.6551 | −0.038137 | 0.94479 |
| Smoking (%) | 101.315 | <0.000 | 0.5459 | 0.019259 | −0.016761 |
| Non-smoking (%) | 390.327 | <0.000 | 0.7902 | 0.051071 | −0.087337 |
| Drinking (%) | 58.02 | <0.000 | 0.4013 | 0.013079 | −0.002038 |
| Non-drinking (%) | 461.412 | <0.000 | 0.8027 | 0.056592 | −0.099645 |
| INH (%) | 25.532 | <0.000 | 0.2437 | −0.013242 | 0.74462 |
| RFP (%) | 5.502 | 0.019 | 0.0531 | 0.005063 | 0.1506 |
| EMB (%) | 0.722 | 0.395 | 0.0236 | 0.001139 | 0.057315 |
| SM (%) | 24.756 | <0.000 | 0.1574 | 0.013045 | 0.51201 |
Notes: INH (%), RFP (%), EMB (%), and SM (%) refer to the proportion of primary INH/RFP/EMB/SM resistant TB among total primary DR TB cases, respectively.
Abbreviations: MR-TB, mono-resistant tuberculosis; MDR-TB, multi-resistant tuberculosis; PDR-TB, polydrug resistant tuberculosis; EMB, ethambutol; INH, isoniazid; RIF, rifampin; SM, streptomycin; TB, tuberculosis.
The Temporal Change Trend of Primary Drug Resistance Rate Among the Elderly TB Cases in Shandong, China, 2004–2019*
| Characteristic | Drug Resistance Rate (%) | Change (%) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | ||
| DR-TB (Total) | 29.67 | 20.24 | 20.31 | 14.5 | 19.73 | 10.94 | 10 | 19.08 | 16.72 | 15.57 | 15.77 | 17.11 | 17.26 | 17.87 | 15.70 | 16.67 | −43.82 |
| Type | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference |
| MR-TB (Total) | 26.37 | 14.88 | 13.79 | 7.85 | 11.66 | 7.03 | 5 | 12.5 | 7.62 | 10.78 | 9.32 | 12.83 | 10.68 | 10.66 | 11.43 | 11.20 | −57.53 |
| MDR-TB (Total) | 1.10 | 1.79 | 3.07 | 2.11 | 1.35 | 1.56 | 5 | 1.97 | 4.11 | 2.1 | 2.15 | 0.8 | 3.29 | 2.82 | 1.57 | 2.86 | 160 |
| PDR-TB (Total) | 2.2 | 3.57 | 3.45 | 4.53 | 6.73 | 2.34 | 0 | 4.28 | 4.99 | 2.69 | 4.3 | 3.48 | 3.29 | 4.39 | 2.69 | 2.60 | 18.18 |
| Sex | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference |
| Male | 25.27 | 19.05 | 18.39 | 12.99 | 18.39 | 10.934 | 10 | 17.43 | 15.25 | 13.77 | 13.62 | 13.9 | 15.89 | 15.99 | 13.68 | 14.84 | −41.27 |
| Female | 4.4 | 1.19 | 1.92 | 1.51 | 1.35 | 0 | 0 | 1.64 | 1.47 | 1.8 | 2.15 | 3.21 | 1.37 | 1.88 | 2.02 | 1.82 | −58.11 |
| Cavity | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference |
| Yes | 2.2 | 2.98 | 6.9 | 2.72 | 4.93 | 1.56 | 0 | 3.29 | 4.99 | 5.09 | 6.45 | 5.62 | 7.67 | 7.84 | 6.95 | 7.81 | 255 |
| No | 27.47 | 16.67 | 12.64 | 10.57 | 13 | 9.38 | 10 | 15.46 | 10.85 | 8.98 | 6.45 | 7.49 | 4.93 | 8.15 | 5.61 | 5.47 | −80.09 |
| Smoking | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference |
| Yes | no reference | no reference | no reference | no referencce | 1.35 | 0.78 | 0 | 4.93 | 4.99 | 4.79 | 4.66 | 3.21 | 3.56 | 5.02 | 3.14 | 2.86 | 111.85 |
| No | no reference | no reference | no reference | no reference | 2.24 | 3.91 | 0 | 10.86 | 7.04 | 8.98 | 8.6 | 9.89 | 9.32 | 9.72 | 10.99 | 9.90 | 341.96 |
| Drinking | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference |
| Yes | no reference | no reference | no reference | no reference | 0.9 | 0.78 | 80 | 0 | 2.93 | 2.69 | 4.66 | 2.41 | 2.47 | 2.82 | 2.69 | 1.56 | 73.33 |
| No | no reference | no reference | no reference | no reference | 2.69 | 3.91 | 0 | 10.53 | 8.8 | 11.08 | 8.6 | 10.7 | 10.41 | 11.6 | 11.44 | 10.94 | 306.69 |
| First-line drugs | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference | no reference |
| INH | 19.78 | 14.29 | 12.26 | 9.37 | 13.45 | 7.81 | 10 | 11.51 | 12.61 | 8.38 | 9.32 | 8.02 | 9.32 | 9.09 | 8.30 | 9.64 | −51.26 |
| RFP | 1.1 | 1.79 | 3.45 | 2.72 | 3.14 | 2.34 | 5 | 3.29 | 4.99 | 2.69 | 2.51 | 1.87 | 4.93 | 2.82 | 2.69 | 3.65 | 231.82 |
| EMB | 2.2 | 1.19 | 1.15 | 1.21 | 1.35 | 0 | 0 | 2.3 | 1.76 | 0.6 | 1.79 | 8.02 | 1.64 | 1.57 | 0.90 | 1.04 | −52.73 |
| SM | 10.99 | 9.52 | 12.26 | 10.57 | 9.87 | 4.69 | 5 | 9.54 | 10.56 | 10.18 | 11.47 | 10.96 | 12.05 | 14.73 | 9.87 | 10.42 | −5.19 |
Notes: *The % changes were calculated as follows: (incidence in 2019–incidence in 2004)/incidence in 2004). Primary drug resistance rate (%) were calculated as follows: (the quantity of each DR-TB subgroups/the quantity of corresponding primary TB cases (total) in the same year) × 100%, for example, primary drug resistance rate (%) of female TB cases in 2019 = (the quantity of female DR-TB cases in 2019/the quantity of total female primary TB cases in 2019) × 100%.
Abbreviations: TB, tuberculosis; DR-TB, drug-resistant tuberculosis; MR-TB, mono-resistant tuberculosis; MDR-TB, multi-resistant tuberculosis; PDR-TB, polydrug resistant tuberculosis; EMB, ethambutol; INH, isoniazid; RFP, rifampin; SM, streptomycin.